Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. Issue 2 (28th January 2019)

• Record Type: Journal Article
• Authors: Kinch, Amelie; Sundström, Christer; Baecklund, Eva; Backlin, Carin; Molin, Daniel; Enblad, Gunilla
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 2(2019)
• Page Start: 376
• Page End: 384
• Publication Date: 2019-01-28
• Subjects: PTLD -- lymphoma -- programed death protein 1 -- solid organ transplantation -- LMP1 -- tumor microenvironment; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1480767
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We studied the expression of programed death 1 (PD-1) receptor and its ligands (PD-L1/-L2) by immunohistochemistry and its association with clinicopathological features in 81 posttransplant lymphoproliferative disorders (PTLDs) following solid organ transplantation. Overall, 67% (54/81) of the PTLDs were positive in any of the three immunostainings. PD-1 was detected on tumor-infiltrating cells in 41% (33/81) of the PTLDs. PD-L1 was expressed on ≥5% of the tumor cells in 50% (40/80) and PD-L2 in 32% (23/72) of the PTLDs. All Burkitt lymphomas were PD-L1 negative. Expression of PD-L1 tended to be associated with non-germinal center-type of diffuse large B-cell lymphoma (63% vs. 33% in GC-type, p = .14) and latent membrane protein-1+ PTLD (76% vs. 44% in LPM1-, p = .09). Heart recipients had more frequent PTLDs with PD-1+ microenvironment ( p = .01). The frequent expression of PD-1 or -L1/-L2 in PTLD warrants further clinical evaluation of the efficacy and safety of PD-(L)1 inhibitors for refractory PTLD.